<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="34494">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02657525</url>
  </required_header>
  <id_info>
    <org_study_id>2015-88</org_study_id>
    <nct_id>NCT02657525</nct_id>
  </id_info>
  <brief_title>Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study</brief_title>
  <acronym>AECOPD-IRS</acronym>
  <official_title>Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China-Japan Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China Soong Ching Ling Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China-Japan Friendship Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the demographic characteristics, clinical
      features, diagnoses and treatments of AECOPD hospitalized patients in China, and disease
      prognosis and its economic burden.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>In-hospital mortality</measure>
    <time_frame>12 months</time_frame>
    <description>All-cause and cause-specific mortality will be described.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Readmission</measure>
    <time_frame>12 months</time_frame>
    <description>Readmission rate caused by AECOPD within 1 month after discharged from hospital.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause and cause-specific mortality</measure>
    <time_frame>3 years</time_frame>
    <description>All-cause and cause-specific mortality will be described at different time points (1, 2, 3 years)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of acute exacerbation of COPD</measure>
    <time_frame>3 years</time_frame>
    <description>Frequency of AECOPD recurrence will be described during follow-ups, the date of first recurrence after discharge will be analysed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung function and quality of life assessment</measure>
    <time_frame>3 years</time_frame>
    <description>Lung function will be measured regularly, quality of life will be assessed by questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare costs</measure>
    <time_frame>12 months</time_frame>
    <description>Direct costs of hospital stay will be recorded.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">7600</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        AECOPD-IRS plans to enroll 7600 hospitalized patients (≥ 18 years old with main diagnosis
        as AECOPD). Sample size estimation is based on estimated mortality of AECOPD hospitalized
        patients (~5%). Study patients will be recruited from 40-60 hospitals across China,each
        hospital will recruit 152-190 patients. Hospital selection follows a multi-stage sampling
        strategy.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        ≥18 years of age; hospitalized patients with main diagnosis as AECOPD.

        Exclusion Criteria:

        Patients diagnosed as active pulmonary tuberculosis, or acute left heart failure; Patients
        participating in clinical trials or intervention studies of drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>February 3, 2016</lastchanged_date>
  <firstreceived_date>January 14, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China-Japan Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Chen Wang</investigator_full_name>
    <investigator_title>Prof.Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
